Adjuvant Chemotherapy Is Associated with Improved Survival in Advanced Ampullary Adenocarcinoma—A Population-Based Analysis by the German Cancer Registry Group
Authors:
- Jannis DuhnJDJannis Duhn
- Julia SträsserJSJulia Strässer
- Lennart von FritschLFLennart von Fritsch
- Rüdiger BraunRBRüdiger Braun
- Kim C. HonselmannKHKim C. Honselmann
- Markus KistMKMarkus Kist
- Thaer S. A. AbdallaTAThaer S. A. Abdalla
- Kees Kleihues-Van TolKTKees Kleihues-Van Tol
- Bianca FrankeBFBianca Franke
- Fabian ReinwaldFRFabian Reinwald
- Andrea SackmannASAndrea Sackmann
- Bernd HolleczekBHBernd Holleczek
Open Access
- 30 May 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (11) , 3869
Abstract
Introduction: Ampullary adenocarcinomas (AMPACs) represent rare malignant neoplasms arising in the Ampulla of Vater. Due to a lack of prospective studies and heterogeneous results from retrospective analyses, the outcomes of adjuvant chemotherapy (AC) in AMPAC are unclear. Methods: Pooled, pseudonymized data were retrieved from clinical cancer registries participating in the German Cancer Registry Group of the Association of German Tumor Centers (GCRG/ADT). Patients who underwent surgical resection of AMPACs (ICD-10: C24.1) with subsequent follow-up or AC were included. Patients with 90-day postoperative mortality were excluded. The epidemiologic and histopathologic features as well as the overall survival and recurrences were compared in both groups using R statistics. Results: In total, 830 patients with AMPACs were identified, of which 184 (22.2%) received AC. The surgery + AC patients showed more advanced tumor stages and more pronounced locoregional invasion as compared to the group undergoing surgery alone. AC was independently associated with an improved overall survival (OS) in a multivariable analysis (HR 0.57, p < 0.001), where pT3-4 status, lymph node metastases, vascular invasion, and advanced grading remained independent prognostic factors for OS. In the subgroup analyses, AC was associated with improved OS in the patients with pT3-4 tumors, lymph node metastases, lymphovascular invasion, and advanced grading, or UICC stage III, whereas no association with the OS was observed in the other subgroups. AC was also associated with superior disease-free survival (DFS) in a multivariable analysis. Conclusions: We provide a large-scale population-based analysis of AMPAC patients, showing an association of AC with improved OS in patients with advanced-staged disease or signs of locoregional invasion as compared to surgery alone.Keywords
This publication has 21 references indexed in Scilit:
- Impact of histopathological type on the prognosis of ampullary carcinoma: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2022
- Missing Data in Clinical Research: A Tutorial on Multiple ImputationCanadian Journal of Cardiology, 2021
- Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinomaEuropean Journal of Surgical Oncology, 2020
- Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary CarcinomaJAMA Surgery, 2019
- Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort StudyJournal of Gastrointestinal Surgery, 2017
- Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinomaThe American Journal of Surgery, 2017
- Clinicopathologic and survival analysis of resected ampullary adenocarcinomaJournal of Surgical Oncology, 2016
- Clinical significance of pathologic subtype in curatively resected ampulla of vater cancerJournal of Surgical Oncology, 2011
- Clinicopathologic Analysis of Ampullary Neoplasms in 450 Patients: Implications for Surgical Strategy and Long-Term PrognosisJournal of Gastrointestinal Surgery, 2009
- Cancers of the ampulla of vater: Demographics, morphology, and survival based on 5,625 cases from the SEER programJournal of Surgical Oncology, 2009